Dexamethasone COVID-19 Findings Leave Authorities Bracing for Yet Another Demand Surge
Executive Summary
Regulators whipsawed by COVID-19-related drug shortages are seeking better ways to forecast demand.
You may also be interested in...
COVID-19 Therapeutic Trials: Investigators Should Join Forces Rather Than Conduct Single Site Studies
‘Treacherous combination’ of small clinical trials, lagging enrollment, unreported results and uncompleted trials is hindering COVID-19 research, former FDA Commissioner Califf says. Yale professor calls for a ‘Manhattan Project’ around knowledge and a change in the academic star system.
Quality Lowdown: FDA Defends Nitrosamine Testing Methods While US, EU Enforcement Continues
The crisis of nitrosamine contamination in prescription drug products continues to roil the world’s health authorities and prompts debate on the different approaches used to measure these impurities. Meanwhile, an Austrian firm gets inspected despite the pandemic and yet another homeopathic firm gets an FDA warning letter.
Sandoz Unveils Zero-Profit COVID-19 Portfolio
Lutz Hegemann, chief operating officer for global health at Novartis, says the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.